learn Neem Oil
natural substance from Neem tree with medicinal and pesticidal properties
Search
forLearn
5 / 6 resultslearn sh-Polypeptide-7
learn Osteopontin
signaling protein that, when suppressed, may grow hair by reducing inflammation and stem cell loss
learn Epidermal Growth Factor
learn Thymosin Beta 4
Research
5 / 1000+ resultsresearch Mouse Models of Alopecia Areata: C3H/HeJ Mice Versus the Humanized AA Mouse Model
The humanized AA mouse model is better for testing new alopecia areata treatments.
research The Role of Entrepreneurial Leadership and Innovation in the Future of Therapeutic Dermatology
Entrepreneurial companies are key to advancing dermatology treatments and patient care.
research Spontaneous Intrinsic Aging in Organ-Cultured Human Skin as a Novel Ex Vivo Assay to Test Anti-Aging Actives
The document concludes that a new method has been developed to test anti-aging substances on human skin, showing that these substances can reduce skin aging signs.
research Combination Therapies and the Theoretical Limits of Evidence-Based Medicine
The current system can't fully test all combination treatments, so alternative methods and regulatory flexibility are needed.
research The PDGF/PDGFR Pathway as a Drug Target
The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.
Community Join
5 / 68 resultscommunity Amplifica and AMP-303 clinical phase 1
Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.
community Where are we on SCUBE3? Have they even started clinical trials?
The conversation is about the progress of clinical trials for SCUBE3, a potential hair loss treatment. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.
community Prediction: Scube3 is never coming out
Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.
community Are there any news about scube3? Did they want to start the clinical trials soon?
The conversation is about skepticism regarding new hair loss treatments until they are FDA approved. People have been joking about treatments being 5-7 years away for decades.
community Does RU58841 potentially cause cancer?
RU58841 may pose cancer risks due to its antiandrogen properties and lack of long-term safety data. Using it is considered a high-risk experiment with unknown potential for harm.